Pathogenesis of propylthiouracil-related hepatotoxicity in children: Present concepts

Journal of Pediatric Endocrinology and Metabolism

Volumn 25, Issue 7-8, 2012, Pages 623-630

  Karras, Spiros ^a   Memi, Eleni ^a   Kintiraki, Evangelia ^a   Krassas, Gerasimos E ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

Children; Hepatotoxicity; Pathogenesis; PTU

Indexed keywords

ACYLTRANSFERASE; ANTITHYROID AGENT; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUCURONIC ACID; ISOENZYME; PROPYLTHIOURACIL; T LYMPHOCYTE RECEPTOR; URIDINE DIPHOSPHATE; XENOBIOTIC AGENT;

APOPTOSIS; BODY WATER; CONGENITAL HYPOTHYROIDISM; DRUG ABSORPTION; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GOITER; GRAVES DISEASE; HEREDITY; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; INTESTINE FLORA; LIVER INJURY; LIVER SIZE; LIVER TOXICITY; METABOLIC CLEARANCE RATE; METABOLIC DISORDER; ORGANOGENESIS; OXIDATIVE STRESS; PH; PHYSICAL CHEMISTRY; PROTEIN BINDING; REVIEW; TOXIC HEPATITIS;

ADOLESCENT; AGE OF ONSET; ANTITHYROID AGENTS; CHILD; CONCEPT FORMATION; DRUG-INDUCED LIVER INJURY; HUMANS; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; PROPYLTHIOURACIL;

EID: 84867759889     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2012-0059     Document Type: Review

References (77)

1. Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 1995;7:220-33.
2. Buratti S, Lavine JE. Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Curr Opin Pediatr 2002;14:601-7.
3. Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am 1998;7:109-26.
4. Foley TP. Thyrotoxicosis in childhood. Pediatr Ann 1992;21:43-9.
5. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019-24.
6. Rivkees SA. 63 years and 715 days to the "boxed warning": unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol 2010;2010:658267.
7. Koch L. Therapy: propylthiouracil use associated with severe hepatotoxicity in children. Nat Rev Endocrinol 2010;6:416.
8. Memi E, Karras S, Tzotzas T, Krassas GE. Propylthiouracil hepatitis: report of a case and extensive review of the literature. J Pediatr Endocr Met 2012;25:331-43.
9. Hakkola J. Xenobiotic-metabolizing cytochrome P450 enzymes in the human fetoplacental unit: role in intrauterine toxicity. Crit Rev Toxicol 1998;28:35-72.
10. Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 2011;12:487-97.
11. Seyberth HW, Kauffman RE. Basics and dynamics of neonatal and pediatric pharmacology. Handb Exp Pharmacol 2011;205:3-49.
12. Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003;17:281-99.
13. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005;1:447-71.
14. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002;43(Suppl 3):53-9.
15. Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J Pediatr Gastroenterol Nutr 2008;47:3-10.
16. Farwell AP, Braverman LE. Thyroid and antithyroid drugs. In: Hardman JG, Limbird LE, editors. Goodmans and Gilman's The pharmacological basis of therapeutics, 10th ed. Columbus, Ohio, USA: McGraw-Hill, 2001:1563-96.
17. Anderson GD. Developmental pharmacokinetics. Semin Pediatr Neurol 2010;17:208-13.
18. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009;24:25-36.
19. Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (part III). Clin Pharmakokinet 1988;14:261-86.
20. Ginsberg G, Hattis D, Miller R, Sonawane B. Pediatric pharmacokinetic data: implications for environmental risk assessment for children. Pediatrics 2004;113(Suppl 4):973-83.
21. Wang JF, Chou KC. Molecular modeling of cytochrome P450 and drug metabolism. Curr Drug Metab 2010;11:342-6.
22. Johnson TN. The development of drug metabolising enzymes and their infl uence on the susceptibility to adverse drug reactions in children. Toxicology 2003;192:37-48.
23. Fedejko B, Mazerska Z. [UDP-glucuronyltransferases in detoxifi cation and activation metabolism of endogenous compounds and xenobiotics]. Postepy Biochem 2011;57:49-62 [in Polish].
24. He SM, Zhou ZW, Li XT, Zhou SF. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr Med Chem 2011;18:667-713.
25. Grattagliano I, Bonfrate L, Diogo CV, Wang HH, Wang DQ, et al. Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J Gastroenterol 2009;15:4865-76.
26. Han D, Hanawa N, Saberi B, Kaplowitz N. Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol 2006;291:G1-7.
27. Go YM, Jones DP. Redox control systems in the nucleus: mechanisms and functions. Antioxid Redox Signal 2010;13:489-509.
28. Franco R, Cidlowski JA. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 2009;16:1303-14.
29. Vickers AE, Fisher RL, Sinclair JR. Glutathione modulation and oxidative stress in human liver slices. Curr Drug Discov Technol 2010;7:154-69.
30. Ginsberg G, Hattis D, Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 2004;198:164-83.
31. Monostory K, Dvorak Z. Steroid regulation of drug-metabolizing cytochromes P450. Curr Drug Metab 2011;12:154-72.
32. Sitar DS. Metabolism of thioamide antithyroid drugs. Drug Metab Rev 1990;22:477-502.
33. Williams RH, Kay GA, Jandorf BJ. Thiouracil. Its absorption, distribution, and excretion. J Clin Invest 1944;23:613-27.
34. Chesley LC. Observations on the absorption, apparent volume of distribution and excretion of thiourea. J Biol Clin 1944;23:856-8.
35. Skellern GG, Knight BI, Low CK. The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients. Br J Clin Pharmacol 1980;9:137-43.
36. Okuno A, Taguchi T, Inyaku F, Yano K, Suzuki Y. Pharmacokinetics of propylthiouracil in children and adolescents with Graves disease after a single oral dose. Pediatr Pharmacol (New York) 1983;3:43-7.
37. Huang G. Relation between the dosage of methimazole and its intrathyroidal concentrations. Zhonghua Yi Xue Za Zhi 1991;71:301-3.
38. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-17.
39. Taurog A, Dorris ML. Propylthiouracil and methimazole display contrasting pathways of peripheral metabolism in both rat and human. Endocrinology 1988;122:592-601.
40. Taurog A, Dorris ML, Guzieg FS, Uetrecht JP. Metabolism of 35S-and 14C-labelled propylthiouracil in a model in vitro system containing thyroid peroxidase. Endocrinology 1989;124:3030-7.
41. Ringhand HP, Ritschel WA, Meyer MC. Bioavailability of propylthiouracil in humans. J Pharm Sci 1983;72:1409-12.
42. Twele R, Kern W, Spiteller G. 2-Mercapto-1-methyl-5- methylmercaptoimidazole: a new metabolite of thiamazole. Xenobiotica 1983;13:661-8.
43. Kariya K, Sawahata T, Okuno S, Lee E. Inhibition of hepatic glutathione transferases by propylthiouracil and its metabolites. Biochem Pharmacol 1986;35:1475-9.
44. Yuan L, Kaplowitz N. Glutathione in liver diseases and hepatotoxicity. Mol Aspects Med 2009;30:29-41.
45. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996;10:709-20.
46. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned ? J Clin Endocrinol Metab 1997;82:1727-33.
47. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, et al. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003;37:224-8.
48. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;23:217-26.
49. Rivkees SA, Mattison DR. PTU hepatotoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009;2009:132041.
50. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009;360:1574-5.
51. Testa G. Liver transplantation for propylthiouracil-induced acute hepatic failure. Dig Dis Sci 2003;48:190-1.
52. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009;19:673-4.
53. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-53.
54. Chalasani N, Björnsson E. Risk factors for idiosyncratic druginduced liver injury. Gastroenterology 2010;138:2246-59.
55. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-9.
56. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009;5:374-81.
57. Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly 2010;140:w13080.
58. Ansan H, Ali A, Ali R. Oxygen free radicals and systematic autoimmunity. Clin Exp Immunol 2003;131:398-404.
59. Weetman AP, Holt ME, Campbell AK. Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. Br Med J 1984;288:518-20.
60. Burch HB, Barnes S, Nagy EV. Immunodetection of manganese superoxide dismutase in cultured human retroocular fi broblast using sera directed against the thyrotropin receptor. J Endocrinol Invest 1998;21:48-55.
61. Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinfl ammatory cytokine production. J Exp Med 2011;208:417-20.
62. Roy DN, Mandal S, Sen G, Biswas T. Superoxide anion mediated mitochondrial dysfunction leads to hepatocyte apoptosis preferentially in the periportal region during copper toxicity in rats. Chem Biol Interact 2009;182:136-47.
63. Diesen DL, Kuo PC. Nitric oxide and redox regulation in the liver: part I. General considerations and redox biology in hepatitis. J Surg Res 2010;162:95-109.
64. Diesen DL, Kuo PC. Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention. J Surg Res 2011;167:96-112.
65. Carrion AF, Czul F, Arosemena LR, Selvaggi G, Garcia MT, et al. Propylthiouracil-induced acute liver failure: role of liver transplantation. Int J Endocrinol 2010;2010:910636.
66. Riley RJ, Leeder JS. In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol 1995;99:1-6.
67. Adam J, Pichler WJ, Yerly D. Br J. Delayed drug hypersensitivity: models of T-cell stimulation. Clin Pharmacol 2011;71:701-7.
68. Gill R, Tsung A, Billiar T. Linking oxidative stress to infl ammation: Toll-like receptors. Free Radic Biol Med 2010;48:1121-32.
69. Jaeschke H. Reactive oxygen and mechanisms of infl ammatory liver injury: present concepts. J Gastroenterol Hepatol 2011;26(Suppl 1):173-9.
70. Poli G. Pathogenesis of liver fi brosis: role of oxidative stress. Mol Aspects Med 2000;21:49-98.
71. Dröge W. Oxidative stress and aging. Adv Exp Med Biol 2003;543:191-200.
72. Tsukamoto H. Redox regulation of cytokine expression in Kupffer cells. Antioxid Redox Signal 2002;4:741-8.
73. Agundez JA, Ladero JM. Glutathione S-transferase GSTT1 and GSTM1 allozymes: beyond null alleles. Pharmacogenomics 2008;9:359-63.
74. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35:883-9.
75. Andrade RJ, Lucena MI, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, et al. HLA class II genotype infl uences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004;39:1603-12.
76. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004;39:1430-40.
77. Boelsterli UA, Lim PL. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 2007;220:92-107.